miricorilant
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2019 (NCT03818256)
Timeline
Indications
Mechanism of action
- Glucocorticoid receptorMODULATOR
NR3C1 modulator
Chemistry & pharmacology
Loading structure…
SMILES
O=c1[nH]c(=O)c(Cc2cccc(C(F)(F)F)c2)c([C@H]2CC[C@H](c3ccccc3)CC2)[nH]1- Mol. weight
- 428.45 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297602 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06947304 | Phase 1 | Aug 22, 2025 | Corcept Therapeutics, University of Missouri |
| NCT06108219 | Phase 2 | Oct 25, 2023 | Corcept Therapeutics |
| NCT05712265 | Phase 1 | Jan 24, 2023 | Corcept Therapeutics |
| NCT05553470 | Phase 1 | Oct 3, 2022 | Corcept Therapeutics |
| NCT05117489 | Phase 1 | Nov 30, 2021 | Corcept Therapeutics |
| NCT04672499 | Phase 1 | Apr 27, 2020 | Corcept Therapeutics, Quotient |
| NCT03818256 | Phase 2 | Mar 31, 2019 | Corcept Therapeutics |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Corcept Therapeutics | For profit | 7 | 7 | 2 | 2019 |
| Quotient | For profit | 1 | 0 | 1 | 2020 |
| University of Missouri | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1